{"filing":{"accession_number":"0001493152-26-036104","cik":"0000946644","ticker":"AIM","company_name":"AIM ImmunoTech Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-07-31","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036104/form8-k.htm"},"events":[{"id":24876,"run_id":22551,"accession_number":"0001493152-26-036104","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses termination of an Equity Distribution Agreement (ATM offering facility) with Maxim Group LLC, effective August 15, 2026. The company sold 3.2 million shares for $2.8 million gross proceeds under the agreement from April 2025 to July 2026. While Item 1.02 addresses termination of material definitive agreements, this is fundamentally a financial event involving the loss of a capital-raising mechanism rather than a debt covenant breach, impairment, or other specific financial category. The termination is material as it eliminates the company's ability to conduct future at-the-market offerings, affecting its capital access strategy.","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":25568,"accession_number":"0001493152-26-036104","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of an Equity Distribution Agreement (ATM offering facility) with Maxim Group LLC, effective August 15, 2026. The company sold 3.2 million shares for $2.8 million gross proceeds under the agreement from April 2025 to July 2026. While Item 1.02 addresses termination of material definitive agreements, this is fundamentally a financial event involving the loss of a capital-raising mechanism rather than a debt covenant breach, impairment, or other specific financial category. The termination is material as it eliminates the company's ability to conduct future at-the-market offerings, affecting its capital access strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:32:11.912056+00:00","company_name":"AIM ImmunoTech Inc.","ticker":"AIM","filing_date":"2026-08-05"}]}